AZ Labs is developing a novel delivery system to deliver zinc directly into the lungs helps alleviate symptoms of the common cold/viral infections
The homeopathic product, Azvirex™ utilizes simple vaporization technology to deliver atomized zinc directly into the targeted organ, the lungs.
LANOIR, N.C., April 17, 2020 /PRNewswire-PRWeb/ -- AZ Labs is developing this innovative, patent pending, formulation as a homeopathic solution that helps alleviate symptoms of viral respiratory ailments. The product, Azvirex™, is intended to be a preventative or therapeutic aid that inhibits viral replication. Azvirex™, is in final development stages and agreements are in place with contract manufacturers to manufacture, package and market this unique homeopathic remedy.
The homeopathic product, Azvirex™ utilizes simple vaporization technology to deliver atomized zinc directly into the targeted organ, the lungs. This directeded delivery of zinc to the lower respiratory tract is intended to prevent and/or inhibit viral replication pathways of RNA viruses and other viral types (2,3,4) as well as some bacteria.
The Azvirex ™ formulation is based on multiple in-vitro and in-vivo studies that have demonstrated the efficacy of zinc ions in preventing and or inhibiting viral replication. Peer reviewed studies have shown zinc is involved in numerous aspects of cellular metabolism and is required for the catalytic activity of approximately 100 enzymes (5,6) and plays a key role in immune function (7,8).
Treatment with Azvirex ™ should provide similar or superior effectiveness for preventing or limiting the duration of the common cold (9) as compared to zinc lozenges and nasal sprays as it directly delivers zinc ions to both the upper and lower respiratory tract. These are the critical areas commonly affected by viral infections
For more information regarding AZ Labs Azvirex ™ formula, please visit http://www.azlabsnc.com. If you have any questions regarding information in the press release, please contact Max Azevedo at (828) 292-1905
1. Efficacy of Zinc Against Common Cold Viruses: An Overview Darrell Hulisz
2.Te Velthuis A., Van Den Worm S, Sims A, Barie R, Snijder E, Van Hermert M. Zn2+ inhibits coronavirus and arterivrus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture. PLoS Pathog. 2010 Nov: 6(11) [ 1 0.13 71 ljouma l.pp at.100 1176 ]
3.Suara RO, Crowe JE Jr. Effects of zinc salts ofrespiratory syncytical virus replication. Antimicrob Agents Chemother., 2004 Mar, 48(3): 783-90.
4.Ishida, T. Antiviral activities of Zn2+ ions for viral prevention, replication, capsid protein and intracellular proliferation of viruses. WSN 97, 2018: 28-50.
5.Sandstead HH. Understanding zinc: recent observations and interpretations. J Lab Clin Med 1994;124:322-7. [PubMed abstract]
6.Institute of Medicine, Food and Nutrition Board. Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. Washington, DC: National Academy Press, 2001.
7.Solomons NW. Mild human zinc deficiency produces an imbalance between cell-mediated and humoral immunity. Nutr Rev 1998;56:27-8. [PubMed abstract]
8.Prasad AS. Zinc: an overview. Nutrition 1995;11:93-9. [PubMed abstract]
9.Prasad AS, Beck FW, Bao B, Snell D, Fitzgerald JT. Duration and severity of symptoms and levels of plasma interleukin-1 receptor antagonist, soluble tumor necrosis factor receptor, and adhesion molecules in patients with common cold treated with zinc acetate. J Infect Dis 2008 ;197:795-802. [PubMed abstract]
SOURCE AZ Labs
Share this article